Literature DB >> 31049845

Immune Cell Signaling by Helicobacter pylori: Impact on Gastric Pathology.

Nicole Blaser1, Steffen Backert1, Suneesh Kumar Pachathundikandi2.   

Abstract

Helicobacter pylori represents a highly successful colonizer of the human stomach. Infections with this Gram-negative bacterium can persist lifelong, and although in the majority of cases colonization is asymptomatic, it can trigger pathologies ranging from chronic gastritis and peptic ulceration to gastric cancer. The interaction of the bacteria with the human host modulates immune responses in different ways to enable bacterial survival and persistence. H. pylori uses various pathogenicity-associated factors such as VacA, NapA, CGT, GGT, lipopolysaccharide, peptidoglycan, heptose 1,7-bisphosphate, ADP-heptose, cholesterol glucosides, urease and a type IV secretion system for controlling immune signaling and cellular functions. It appears that H. pylori manipulates multiple extracellular immune receptors such as integrin-β2 (CD18), EGFR, CD74, CD300E, DC-SIGN, MINCLE, TRPM2, T-cell and Toll-like receptors as well as a number of intracellular receptors including NLRP3, NOD1, NOD2, TIFA and ALPK1. Consequently, downstream signaling pathways are hijacked, inducing tolerogenic dendritic cells, inhibiting effector T cell responses and changing the gastrointestinal microbiota. Here, we discuss in detail the interplay of bacterial factors with multiple immuno-regulatory cells and summarize the main immune evasion and persistence strategies employed by H. pylori.

Entities:  

Keywords:  Inflammasome; PAMP; PRR; T4SS; TLR

Mesh:

Substances:

Year:  2019        PMID: 31049845     DOI: 10.1007/5584_2019_360

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  8 in total

Review 1.  The immune microenvironment in gastric adenocarcinoma.

Authors:  Yana Zavros; Juanita L Merchant
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2022-03-14       Impact factor: 73.082

Review 2.  Helicobacter pylori and the Role of Lipopolysaccharide Variation in Innate Immune Evasion.

Authors:  Daniel Sijmons; Andrew J Guy; Anna K Walduck; Paul A Ramsland
Journal:  Front Immunol       Date:  2022-05-13       Impact factor: 8.786

Review 3.  Proteolytic Landscapes in Gastric Pathology and Cancerogenesis.

Authors:  Sabine Bernegger; Miroslaw Jarzab; Silja Wessler; Gernot Posselt
Journal:  Int J Mol Sci       Date:  2022-02-22       Impact factor: 5.923

4.  Presence of Helicobacter Species in Gastric Mucosa of Human Patients and Outcome of Helicobacter Eradication Treatment.

Authors:  Rita Matos; Emily Taillieu; Sofie De Bruyckere; Chloë De Witte; Alexandra Rêma; Hugo Santos-Sousa; Jorge Nogueiro; Celso A Reis; Fátima Carneiro; Freddy Haesebrouck; Irina Amorim; Fátima Gärtner
Journal:  J Pers Med       Date:  2022-01-29

Review 5.  Homeostasis and Cancer Initiation: Organoids as Models to Study the Initiation of Gastric Cancer.

Authors:  Sulaimon Idowu; Paul P Bertrand; Anna K Walduck
Journal:  Int J Mol Sci       Date:  2022-03-03       Impact factor: 5.923

6.  Efficacy and safety of Zuojin Pill for chronic gastritis: Protocol for a systematic review of randomized controlled trials.

Authors:  Jianglong Shi; Liyun Liu; Jian Li; Xiaoju Ma; Hairong Qiu; Tao Shen
Journal:  Medicine (Baltimore)       Date:  2020-07-17       Impact factor: 1.817

7.  Helicobacter pylori Dampens HLA-II Expression on Macrophages via the Up-Regulation of miRNAs Targeting CIITA.

Authors:  Gaia Codolo; Marta Toffoletto; Francesco Chemello; Sara Coletta; Gemma Soler Teixidor; Greta Battaggia; Giada Munari; Matteo Fassan; Stefano Cagnin; Marina de Bernard
Journal:  Front Immunol       Date:  2020-01-08       Impact factor: 7.561

8.  Rabeprazole inhibits inflammatory reaction by inhibition of cell pyroptosis in gastric epithelial cells.

Authors:  Jing Xie; Long Fan; Liya Xiong; Peiyu Chen; Hongli Wang; Huan Chen; Junhong Zhao; Zhaohui Xu; Lanlan Geng; Wanfu Xu; Sitang Gong
Journal:  BMC Pharmacol Toxicol       Date:  2021-07-15       Impact factor: 2.483

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.